16.17
전일 마감가:
$16.02
열려 있는:
$15.82
하루 거래량:
621.80K
Relative Volume:
1.58
시가총액:
$5.73B
수익:
$5.10B
순이익/손실:
$-352.00M
주가수익비율:
-15.87
EPS:
-1.0189
순현금흐름:
$-66.14M
1주 성능:
-2.47%
1개월 성능:
-8.39%
6개월 성능:
+6.45%
1년 성능:
+4.39%
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
BLCO
Bausch Lomb Corp
|
16.17 | 5.68B | 5.10B | -352.00M | -66.14M | -1.0189 |
|
ISRG
Intuitive Surgical Inc
|
479.93 | 169.66B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
156.53 | 44.97B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
75.01 | 36.92B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
43.59 | 34.30B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
227.41 | 33.20B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Neutral |
| 2025-05-02 | 재확인 | H.C. Wainwright | Buy |
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Market Shifts and Deb - AD HOC NEWS
RBC reiterates Bausch & Lomb stock rating on DED rival delay - Investing.com Australia
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
RBC reiterates Bausch & Lomb stock rating on DED rival delay By Investing.com - Investing.com South Africa
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Slowdown and D - AD HOC NEWS
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position - AOL.com
Bausch + Lomb Corporation (NYSE:BLCO) Sees Large Decline in Short Interest - MarketBeat
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Shifts - AD HOC NEWS
Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness - Yahoo Finance
Bausch + Lomb Corporation $BLCO Shares Purchased by Compass Rose Asset Management LP - MarketBeat
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch & Lomb (BLCO) legal chief buys shares and receives 14,600 matching RSUs - Stock Titan
Bausch And Lomb (NYSE:BLCO) Glaucoma Moves Catch Market Eyes Nyse Composite Today - Kalkine Media
Bausch & Lomb (NYSE: BLCO) CFO buys 4,000 shares, gets 4,000 RSUs - Stock Titan
Bausch & Lomb (BLCO) CEO buys 14,700 shares and receives matching RSUs - Stock Titan
Bausch + Lomb Corporation - Baystreet.ca
Inside Bausch + Lomb’s glaucoma webinar on new treatments - Stock Titan
Bausch + Lomb Launches R&D "Teach-in" Webinar Series - Yahoo Finance
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Latest Revenue And Net Loss Update - Yahoo Finance
Short Covering: Will Bausch Lomb Corporation outperform its industry peersJuly 2025 Levels & Fast Moving Market Watchlists - baoquankhu1.vn
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know - Finviz
Insider Buying: Ross Thomas W. Sr. Acquires Shares in Bausch & L - GuruFocus
Director adds BLCO stake with 4,500-share buy and 4,500 RSUs grant - Stock Titan
Potential Bausch + Lomb Separation Reframes Bausch Health - simplywall.st
Insider Buying: Eduardo Alfonso Acquires Shares of Bausch & Lomb Corp (BLCO) - GuruFocus
[Form 4] Bausch & Lomb Corp Insider Trading Activity - Stock Titan
Bausch & Lomb (NYSE: BLCO) director buys shares, gets RSUs - Stock Titan
BLCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP disposes shares for taxes - Stock Titan
Bausch & Lomb (BLCO) officer has shares withheld for RSU tax - Stock Titan
Tax-withholding share moves by Bausch & Lomb (NYSE: BLCO) executive - Stock Titan
Bausch & Lomb (BLCO) EVP uses share withholding to cover tax on RSU vesting - Stock Titan
Bausch & Lomb (BLCO) EVP uses shares for tax withholding on RSU vesting - Stock Titan
CFO tax share withholding at Bausch & Lomb (BLCO) after RSU vesting - Stock Titan
Bausch & Lomb (BLCO) CEO uses common shares to cover RSU tax - Stock Titan
Bausch & Lomb (BLCO) SVP awarded 18,253 restricted share units in Form 4 - Stock Titan
Executive at Bausch & Lomb (NYSE: BLCO) granted 32,710 restricted share units - Stock Titan
Bausch & Lomb (NYSE: BLCO) EVP awarded 35,046 restricted share units - Stock Titan
327,102-share RSU award to Bausch & Lomb (BLCO) CEO Brent Saunders - Stock Titan
Bausch + Lomb Corp. Hits New 52-Week High at $18.91 - Markets Mojo
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth - Insider Monkey
Bausch & Lomb (BLCO) CFO receives 81,775 RSU award, boosting holdings - Stock Titan
Bausch + Lomb stock hits 52-week high at $18.86 - Investing.com Australia
Bausch + Lomb stock hits 52-week high at $18.86 By Investing.com - Investing.com Canada
Bausch & Lomb (BLCO) CEO uses 65,444 shares to cover tax withholding - Stock Titan
Is Expert Backing Of LUMIFY’s Safety Profile Quietly Shaping Bausch + Lomb’s Consumer Strategy (BLCO)? - simplywall.st
5 Revealing Analyst Questions From Bausch + Lomb's Q4 Earnings Call - Finviz
Director Steven Collis adds BLCO stake with 15,000-share buy and RSU grant - Stock Titan
Director boosts Bausch & Lomb (BLCO) stake with share buy and matching RSUs - Stock Titan
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):